11 May 2024 - 12 May 2024
08:00 AM - 02:00 PM
05th Knowledge Series for Genitourinary Cancers - Best of 2023
Program Director: Dr Kumar Prabhash, Dr. Sudhir Kumar Rawal
05th Knowledge Series for Genitourinary Cancers - Best of 2023 Day 1|| 11th & 12th May ,2024 Venue- The Pride Aero City Delhi
05th Knowledge Series for Genitourinary Cancers - Best of 2023 - Day 2 || 12th May, 2024
Date : 12 May 2024
Urothelial Cancer Breakthroughs: Gemcitabine-Docetaxel vs BCG - Insights from Dr. Shrikanth Atluri | 12:00 AM - 12:00 AM |
DaBlaCa-13 Study: Mitomycin Chemoresection in Bladder Cancer by Dr. Milap Shah | 12:00 AM - 12:00 AM |
Radical Cystectomy vs Trimodality Therapy in Bladder Cancer: Propensity Score Analysis | CRSF 2024 | 12:00 AM - 12:00 AM |
WOG S1011: Standard vs Extended Lymphadenectomy in Radical Cystectomy - Phase III Trial | CRSF 2024 | 12:00 AM - 12:00 AM |
Robot-Assisted vs Open Radical Cystectomy: 3-Year Outcomes | CRSF 2024 Urothelial Cancer Session | 12:00 AM - 12:00 AM |
UGN-101 for Chemoablation in Upper Tract Urothelial Carcinoma: OLYMPUS Trial Results | CRSF 2024 | 12:00 AM - 12:00 AM |
Bladder-Sparing Radiotherapy: A Radical Cystectomy Alternative | CRSF Genitourinary Cancer Insights | 12:00 AM - 12:00 AM |
Expert Insights on Urothelial Cancer: CRSF Genitourinary Cancers Knowledge Series - Day 2 Highlights | 12:00 AM - 12:00 AM |
Expert Panel Discussion on Genitourinary Cancers | CRSF 2024 Knowledge Series - Day 2 Highlights | 12:00 AM - 12:00 AM |
Take Home Messages from CRS 2024: Key Insights on Genitourinary Cancers | Day 2 Highlights | 12:00 AM - 12:00 AM |
Pharma Sponsored Insights on Urothelial Metastatic Cancer | CRSF 2024 Knowledge Series - Day 2 | 12:00 AM - 12:00 AM |
Exploring CAR T Cell Therapy for Urothelial Metastatic Cancer | CRS 2024 Knowledge Series - Day 2 | 12:00 AM - 12:00 AM |
Dr Annu Rajpurohit: HER2 & PD-L1 in Advanced Bladder Cancer: Insights from CRS 2024 | CRSF | 12:00 AM - 12:00 AM |
Phase 3 THOR Study Results: Erdafitinib vs. Chemotherapy in Advanced Urothelial Cancer | CRSF 2024 | 12:00 AM - 12:00 AM |
EV-302/KEYNOTE-A39:Enfortumab Vedotin+Pembrolizumab vs. Chemotherapy in Metastatic Urothelial Cancer | 12:00 AM - 12:00 AM |
Nivolumab + Gemcitabine-Cisplatin vs. Gemcitabine-Cisplatin in Metastatic Urothelial Cancer | CRSF | 12:00 AM - 12:00 AM |
Expert Panel Discussion: Insights on Urothelial Cancers | CRSF 2024 Knowledge Series Day 2 | 12:00 AM - 12:00 AM |
UNITE Study: Enfortumab Vedotin After Avelumab in Advanced Urothelial Carcinoma | CRSF 2024 | 12:00 AM - 12:00 AM |
Chemoradiotherapy for Locoregionally Advanced Penile Carcinoma: Insights from CRSF 2024 | 12:00 AM - 12:00 AM |
Dr. Priti Agarwal: Predicting Relapse in Stage I Testicular Seminoma: Key Findings from CRS 2024 | 12:00 AM - 12:00 AM |
Dr. Nandini Menon: Interactive Quiz on Genitourinary Cancers: Test Your Knowledge with CRS 2024! | 12:00 AM - 12:00 AM |
Closing Remarks by Dr. Nandini Menon: Reflections and Future Directions | CRSF 2024 | 12:00 AM - 12:00 AM |
05th Knowledge Series for Genitourinary Cancers - Best of 2023 - Day 1 || 11th May, 2024
Date : 11 May 2024
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial | 09:52 AM - 09:59 AM |
CRSF 2024: Exciting Session | Knowledge Series for Genitourinary Cancers Day 1 with Dr. Mondal | 12:00 AM - 12:00 AM |
Quiz for Presenters at CRSF 2024 | Hosted by Dr. Kunal Jobanputra | 02:45 PM - 03:00 PM |
Pharma Sponsored Session 3 at CRSF 2024 | Key Insights with Dr. Akhil Kapoor | 12:00 AM - 12:00 AM |
Upfront Cytoreductive Nephrectomy vs. Targeted Therapy for Metastatic RCC | Insights from CRSF 2024 | 12:00 AM - 12:00 AM |
SESSION 5: Real-World Outcomes for Elderly Patients with Metastatic RCC| Dr. Sandeep Batra, Gurugram | 12:00 AM - 12:00 AM |
SESSION 5: CABOSUN II & KEYNOTE-B61 Results for Non-Clear Cell RCC| Dr Kunal Jonbanputra, MOC Mumbai | 12:00 AM - 12:00 AM |
SESSION 5: CMB588 + Cabozantinib + Nivolumab for mRCC | ASCO GU 2023 | 12:00 AM - 12:00 AM |
SESSION 5: Subcutaneous vs Intravenous Nivolumab in Metastatic RCC | CheckMate67T & LITESPARK-005 | 12:00 AM - 12:00 AM |
SESSION 5: Upfront Cytoreductive Nephrectomy in Metastatic RCC | 05th Knowledge Series | 12:00 AM - 12:00 AM |
SESSION 4: Panel Discussion on Renal Cell Carcinoma Abstracts | Moderator Dr. Srivatsan Narsimhan | 12:00 AM - 12:00 AM |
Expert Comments on Renal Cell Carcinoma | Dr. Anant Kumar, Dr. Rajesh Taneja, Dr. Subhash Gupta | 12:00 AM - 12:00 AM |
Adjuvant Nivolumab + Ipilimumab vs Placebo in Localized Renal Cell Carcinoma | Dr. Suparna Rao | 12:00 AM - 12:00 AM |
Off-Clamp vs On-Clamp Robot-Assisted Partial Nephrectomy | Dr. Mayank Aggarwal |5th Knowledge Series | 12:00 AM - 12:00 AM |
Local Tumor Destruction vs Partial Nephrectomy in T1a Renal Cell Carcinoma | Dr. Vikas Agarwal | 12:00 AM - 12:00 AM |
Focal Ablative Radiosurgery for Kidney Cancers | Dr. Mangesh Patil | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Study on Robot-Assisted vs Conventional Nephrectomy | Dr. Himanshu Pandey | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Panel Discussion on Genitourinary Cancers | Dr. Akhil Kapoor | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Take Home Message from SESSION 3: Metastatic Prostate Cancer| Dr. Vineet Talwar|5th Knowledge Series | 12:00 AM - 12:00 AM |
Importance of Molecular Testing in Advanced Prostate Cancer| Dr. Santosh Menon |5th Knowledge Series | 12:00 AM - 12:00 AM |
SESSION 3: Panel Discussion on Metastatic Prostate Cancer | 05th Knowledge Series | Dr. Akhil Kapoor | 12:00 AM - 12:00 AM |
Stereotactic Body Radiation & Abiraterone for Oligometastatic Prostate Cancer | Dr. Mohd Shuaib | 12:00 AM - 12:00 AM |
PSMAfore Trial & Enzalutamide with 177Lu-PSMA-617 for mCRPC | Dr. Dharmender Malik | 05th Knowledge | 12:00 AM - 12:00 AM |
BRCAAway Trial & Talazoparib Plus Enzalutamide in mCRPC | Dr. Pooja Gupta | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Biweekly vs Triweekly Cabazitaxel & Androgen Receptor Pathway Inhibitors for mCRPC|Dr. Sunil Chopade | 12:00 AM - 12:00 AM |
Impact of Relugolix vs. Leuprolide on Quality of Life in Advanced Prostate Cancer | Dr. Peush Bajpai | 12:00 AM - 12:00 AM |
Phase 3 Studies on mCRPC Treatments | Dr. Amit Kumar | 5th Knowledge Series on Genitourinary Cancers | 12:00 AM - 12:00 AM |
Take Home Message on Prostate Non Metastatic | Dr. Kirthi Koushik | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Take Home Message on Prostate Non Metastatic | Dr. Ravi Chandran K | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Panel Discussion on Prostate Non Metastatic|Dr. Siddharth Yadav & Expert Panel|05th Knowledge Series | 12:00 AM - 12:00 AM |
Expert Comments on Prostate Non Metastatic | Dr. Amlesh Seth, Dr. Hemang Bakshi, Dr. Shikha Goyal | 12:00 AM - 12:00 AM |
Unconventional Histology in Localized Prostate Cancer | Dr. Harshit Garg | 05th Knowledge Series | 12:00 AM - 12:00 AM |
15-Year Outcomes of Robotic Radical Prostatectomy | Dr. Mahendra Pal | 05th Knowledge Series | 12:00 AM - 12:00 AM |
Functional Outcomes After Localized Prostate Cancer Treatment | Dr. Shashank Agrawal | 5th Knowledge | 12:00 AM - 12:00 AM |
Radiotherapy & Brachytherapy | Dr. Bharti Devnani | 05th Knowledge Series on Genitourinary Cancers | 12:00 AM - 12:00 AM |
15Year Outcomes of PROTECT Trial| Dr. Vishnu Prasad | 05th Knowledge Series on Genitourinary Cancers | 12:00 AM - 12:00 AM |
05th Knowledge Series on Genitourinary Cancers | Take Home Message by Dr. Rahul Jena | 12:00 AM - 12:00 AM |
05th Knowledge Series on Genitourinary Cancers | Prostate Non Metastatic Panel Discussion | Day 1 | 12:00 AM - 12:00 AM |
05th Knowledge Series on Genitourinary Cancers | Prostate - Non Metastatic | Expert Comments | 12:00 AM - 12:00 AM |
05th Knowledge Series on Genitourinary Cancers - Best of 2023 | Day 1 | Dr. Srivatsan Ramani | 12:00 AM - 12:00 AM |
Program Director:
Dr Kumar Prabhash, Dr. Sudhir Kumar Rawal
Contact Person
Vishal Sisodia
info@hcmpl.com
+918700379879
Download